Meeting
2020 Genitourinary Cancers Symposium
A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract.
Authors
Michal Sarfaty
Memorial Sloan Kettering Cancer Center, New York, NY
Michal Sarfaty , Irina Ostrovnaya , Min Yuen Teo , Gopa Iyer , Chung-Han Lee , Vanessa Peters , Jennifer Durocher , Ashley Marie Regazzi , Asia S. McCoy , Grace Hettich , Hikmat Al-Ahmadie , Joshua Chaim , Dean F. Bajorin , Jonathan E. Rosenberg , Samuel Aaron Funt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03430895
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 514)
Abstract #
514
Poster Bd #
J15
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).
First Author: Chee Khoon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
First Author: Keun-Wook Lee
First Author: B.J. Rimel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.
First Author: Luchia Andemicael